Clinical trials: Elderly Infection
HIV-1 Infection
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
This is an observational, non-comparative, multicenter, open-label study. Participants will be treated with Raltegravir according to standard clinical practice, and monitored over a total period of 96 weeks.
- Trial name
- WIP (NCT01213316)
- Testing
- Raltegravir
- Volunteers
- 451 people
- Sponsor
- Merck Sharp & Dohme LLC
Influenza
A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults
This study will assess the Efficacy, Safety and Tolerability profile of CSL's Influenza Vaccine administered intramuscularly against laboratory-confirmed influenza illness in a population defined as being not at risk of severe…
- Trial name
- CSL's IVV (NCT00562484)
- Testing
- CSL Limited Influenza Vaccine
- Where
- 24 sites in Australia, New Zealand
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Seqirus
Herpes Zoster
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years
The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune responses and the safety profiles of the…
- Trial name
- NCT00802464
- Testing
- Herpes zoster vaccine GSK1437173A
- Where
- 12 sites in United States, Czechia and 1 more
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bacterial Infections
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points.
- Trial name
- NCT00678106
- Testing
- Dalbavancin
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Seasonal Influenza, Influenza
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
This study aims to evaluate the immunogenicity, by means of cell mediated immunity (CMI) and hemagglutination inhibition (HI) assay, and also the safety of a MF59C.1-adjuvanted subunit influenza vaccine compared with a…
- Conditions
- Seasonal Influenza, Influenza, Influenza Due to Unspecified Influenza Virus, Human Influenza
- Trial name
- NCT01342796
- Testing
- MF59C.1-adjuvanted subunit influenza vaccine, Sub unit, Inactivated, Influenza vaccine
- Where
- 2 sites in Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
The purpose of the study is to evaluate the safety and immunogenicity of GSK Biologicals' influenza vaccine GSK2340272A.
- Trial name
- NCT00951041
- Testing
- GSK investigational vaccine GSK2340272A, GSK investigational vaccine GSK2340269A
- Where
- 3 sites in Germany
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus, Acellular Pertussis
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
This phase IIIb, observer-blind study will evaluate the immunogenicity and safety of GSK Biologicals' Boostrix® vaccine in adults (extending indication) aged 65 years or older.
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines
- Trial name
- NCT00835237
- Testing
- Boostrix®, Decavac™
- Where
- 24 sites in United States
- Volunteers
- 1,332 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after…
- Trial name
- NCT00538473
- Testing
- GSK Biologicals' influenza vaccine GSK576389A, Fluarix™
- Where
- Belgium
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Meningococcal Infection
Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®
The study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 15 to 23 years (not yet 24 years) who had been vaccinated five years previously in Study MTA02 and did not participate in Study MTA19…
- Trial name
- NCT00269477
- Testing
- Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 8 sites in United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections, Papillomavirus
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.
The main aim of this vaccine is to prevent cervical cancer in women. However, it could also be relevant to vaccinate selected groups of males.
- Trial name
- NCT00309166
- Testing
- Cervarix vaccine, Engerix-B vaccine
- Where
- 5 sites in Finland
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Immunodeficiency Virus (HIV) Infection
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to <12 years and weighing <45 kg, who are treatment-naive (TN) or have been…
- Trial name
- NCT04375800
- Testing
- Doravirine, 2 NRTIs, DOR/3TC/TDF
- Where
- 26 sites in United States, Colombia and 6 more
- Volunteers
- 84 people
- Sponsor
- Merck Sharp & Dohme LLC
Complicated Infection, Bacterial Infections
To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)
This is a randomised, double-blind, 3-part study designed to investigate the safety and tolerability of ATM-AVI. The study aims to characterise the pharmacokinetics of ATM-AVI, when both drugs are administered alone (ATM or AVI)…
- Trial name
- NCT01689207
- Testing
- Avibactam (AVI), Aztreonam (ATM), combination of Aztreonam - Avibactam (ATM-AVI)
- Where
- United Kingdom
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza, Human
A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA)…
- Trial name
- NCT06431607
- Testing
- F2G22B/DL001Z, F2H23D/DL001Z-NH, F2H23B/DL001Z-NH
- Where
- 18 sites in United States
- Volunteers
- 845 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or Above
This study is designed to test the immunogenicity and reactogenicity of the Fluarix™/Influsplit SSW® containing the influenza strains recommended for the 2007-2008 season.
- Trial name
- NCT00476307
- Testing
- Fluarix™/Influsplit SSW® 2007/2008
- Where
- 3 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia…
- Trial name
- NCT04899336
- Testing
- ExPEC9V
- Where
- 374 sites in United States, Australia and 19 more
- Volunteers
- 17,797 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
COVID-19, Viral Respiratory Illnesses
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF residents.
- Trial name
- NCT04343248
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 4 sites in United States
- Volunteers
- 190 people
- Sponsor
- Romark Laboratories L.C.
HPV Infections, Cervical Cancer Stage IIa
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05027776
- Testing
- 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years
- Where
- China
- Volunteers
- 1,348 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Bacterial Infections
Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection
This is an open-label, single-arm, pharmacokinetic and safety study of Likmez® in pediatric patients aged 12 months to <4 years with anaerobic bacterial infection
- Trial name
- NCT07146217
- Testing
- Likmez® (metronidazole) Oral Suspension
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Saptalis Pharmaceuticals LLC
Herpes Zoster
Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years
The purpose of this study was to assess vaccine efficacy (VE), ability to generate immune response and safety of two doses of the recombinant subunit zoster vaccine (RZV) for prevention of Herpes Zoster (HZ) in Chinese adults…
- Trial name
- NCT04869982
- Testing
- RZV
- Where
- 6 sites in China
- Volunteers
- 6,138 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects
The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the licensed seasonal flu vaccine, as measured by hemagglutination inhibition (HAI) at 21 days post…
- Trial name
- NCT01411358
- Testing
- non-elderly aged between 18 and 60, elderly aged over 60
- Where
- Taiwan
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.